CORT - Corcept Appoints Roberto Vieira as President Oncology | Benzinga
MENLO PARK, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the appointment of Roberto Vieira as President, Oncology. He will report to Joseph K. Belanoff, MD, Corcept's Chief Executive Officer, and join the company's Executive Team.
Mr. Vieira joins Corcept from Mirati Therapeutics, Inc., where he served as Senior Vice President of U.S. Commercial until earlier this month. At Mirati, Mr. Vieira built the U.S. commercial organization, inclusive of sales, marketing and market access, and successfully led the launch of the company's first targeted cancer therapy for the treatment of advanced non-small cell lung cancer. Mr. Vieira previously spent 15 years at Bristol-Myers Squibb in positions of increasing seniority, including Vice President of Worldwide Oncology Strategy. Prior to that, he also served as General Manager in Europe (The Netherlands) and was part of the leadership team that led the introduction of transformational medicines in the Immuno-Oncology space across a broad range of solid tumors.
"We are thrilled to welcome Roberto to the ...